Passive antibody therapy for infectious diseases

@article{Casadevall2004PassiveAT,
  title={Passive antibody therapy for infectious diseases},
  author={Arturo Casadevall and Ekaterina Dadachova and Liise-Anne Pirofski},
  journal={Nature Reviews Microbiology},
  year={2004},
  volume={2},
  pages={695-703}
}
Antibody-based therapies are currently undergoing a renaissance. After being developed and then largely abandoned in the twentieth century, many antibody preparations are now in clinical use. However, most of the reagents that are available target non-infectious diseases. Interest in using antibodies to treat infectious diseases is now being fuelled by the wide dissemination of drug-resistant microorganisms, the emergence of new microorganisms, the relative inefficacy of antimicrobial drugs in… Expand

Figures, Tables, and Topics from this paper

An augmented passive immune therapy to treat fulminant bacterial infections.
TLDR
The progress made in passive antibody therapy is discussed, the challenges still to be surmounted, and the potential expanded role of an immune-potentiating peptide (bio-molecule) in the quest to utilize and revitalize passive immunization are discussed. Expand
History and Practice: Antibodies in Infectious Diseases.
  • A. Hey
  • Medicine
  • Microbiology spectrum
  • 2015
TLDR
It is time to take a new and revised look into the future to find appropriate niches in infectious diseases where new antibody-based treatments or combinations with existing antibiotics, could prove their value and serve as stepping stones for broader acceptance of the potential for and value of these treatments. Expand
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
TLDR
This review briefly summarizes the recent technological advances in the field of immunoglobulin research, and the current status of mAb-based drugs in clinical trials for HIV and HCV diseases. Expand
Monoclonal antibodies for prophylaxis and therapy of infectious diseases
TLDR
This review aims to highlight the scientific and economic opportunities and obstacles that are encountered in the quest to add mAbs to the armament of anti-infective drugs. Expand
Monoclonal antibody-based therapies for microbial diseases
TLDR
There are signs that the climate for mAb therapeutics in infectious diseases is changing given increasing antibiotic drug resistance, the emergence of new pathogenic microbes for which no therapy is available, and development of mAb cocktail formulations. Expand
Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases
TLDR
Radioimmunotherapy (RIT) has recently been suggested as a novel therapy for the treatment of a variety of infectious diseases, including microbes resistant to conventional antimicrobial therapy and agents of biological warfare. Expand
The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19
TLDR
Three principles of antibody therapy are put forth, namely, specificity, temporal, and quantitative principles, connoting that antibody efficacy requires the administration of specific antibody, given early in course of disease in sufficient amount. Expand
Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
TLDR
As a model organism for studying the efficacy, mechanisms, potential toxicity, and radioresistance to RIT, as well as for comparison of RIT with the existing antimicrobial therapies, this work has chosen the encapsulated yeast Cryptococcus neoformans (CN) as its model organism. Expand
Anti-infective antibodies: a novel tool to prevent and treat nosocomial diseases
TLDR
The interest to revitalize a historical concept of medicine to treat and prevent bacterial infections with antibodies has provoked the interest to improve the understanding of host–parasite interactions and the inclusion of monoclonal antibodies into the arsenal of novel therapies. Expand
Antibody-based inhibitors of HIV infection
TLDR
Whether an antibody-based therapy can be identified (with or without their small molecule brethren) that presents long-term clinical efficacy, low toxicity and minimal risk of clinical failure from viral resistance is challenged. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 78 REFERENCES
Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases
  • A. Casadevall, M. Scharff
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1995
TLDR
It is proposed that for every pathogen there exists an antibody that will modify the infection to the benefit of the host, and such antibodies are potential antimicrobial agents. Expand
Serum therapy revisited: animal models of infection and development of passive antibody therapy
TLDR
Serum therapy for pneumococcal and meningococcal infections is reviewed, with emphasis on the role of the animal models used in their development. Expand
Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers.
TLDR
The historical underpinnings and present and future applications of immune therapy for infectious diseases in light of current challenges to the field are reviewed. Expand
Serum Therapy for Tuberculosis Revisited: Reappraisal of the Role of Antibody-Mediated Immunity againstMycobacterium tuberculosis
TLDR
There is sufficient evidence to conclude that antibody-mediated immunity can modify the course of infection in certain situations, and it is proposed that the role of antibody- mediated immunity to M. tuberculosis be reexamined, using advanced technology. Expand
Feasibility of Radioimmunotherapy of Experimental Pneumococcal Infection
TLDR
A feasibility study establishes that RIT can be applied to the treatment of bacterial infections by evaluating the susceptibility of S. pneumoniae to radiolabeled antibody in vitro and in an animal infection model. Expand
Vaccines for the prevention of diseases caused by potential bioweapons.
TLDR
The need for continued study of host-microbe interaction and the immune response to potential agents of bioterror for the development of new vaccines and immune-based therapies to combat their potential to harm the public is highlighted. Expand
A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis.
TLDR
This is the first report that a human antibody is protective against C. neoformans, and results suggest that human MAbs may have promise as therapeutic reagents against cryptococcosis. Expand
Historic aspects of intravenous immunoglobulin therapy
TLDR
The IVIG preparations revolutionized the management of virtually all immunodeficiency syndromes characterized by failure of antibody responses and in the treatment and prophylaxis of life‐threatening infections in neonates and premature infants is reviewed. Expand
Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection
TLDR
The principle that targeted radiation can be used for the therapy of an infectious disease is established, and it is suggested that it may have wide applicability as an antimicrobial strategy. Expand
Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.
TLDR
It is shown that vaccines composed of the cryptococcal capsular polysaccharide glucuronoxylomannan (GXM), the key C. neoformans virulence factor, elicit protective antibodies in mice, although deleterious antibodies can also be induced. Expand
...
1
2
3
4
5
...